Provided by Tiger Trade Technology Pte. Ltd.

Tema Heart & Health ETF

36.49
+0.46311.29%
Post-market: 36.47-0.0200-0.05%19:30 EDT
Volume:262
Turnover:9.58K
Market Cap:54.37M
PE:- -
High:36.49
Open:36.47
Low:36.47
Close:36.03
52wk High:38.87
52wk Low:29.54
Shares:1.49M
Float Shares:1.49M
Volume Ratio:0.12
T/O Rate:0.02%
Dividend:0.47
Dividend Rate:1.29%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Eli Lilly : Berenberg Raises to Buy from Hold; Raises Target Price to $1,400 from $1,220

THOMSON REUTERS
·
1 hour ago

RBC Capital Sticks to Their Hold Rating for Merck & Company (MRK)

TIPRANKS
·
5 hours ago

RBC Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

TIPRANKS
·
5 hours ago

Lilly Says Foundayo Has Captured over 30% of New US Patients on Oral Weight-Loss Drugs

Reuters
·
10 hours ago

Merck & Co Exec Says Potential 340B and Policy Evolutions Would Create Tailwinds but are not Material to the Business - Morgan Stanley Conf

THOMSON REUTERS
·
11 hours ago

Merck & Co Exec Says Timing for Raising the $70 Bln Forecast is "to be Determined" Adds "It's Coming"

THOMSON REUTERS
·
11 hours ago

Eli Lilly Stock (LLY) Has 45% Upside, Says Citigroup

TIPRANKS
·
11 hours ago

Novo Nordisk is Dropping Some Weight. it Still Faces a Bigger Challenge.

Dow Jones
·
11 hours ago

Eli Lilly Exec Says Co NOW Has More than 30% Share in New Starts Within Oral Obesity Treatment Market -Morgan Stanley Conf

THOMSON REUTERS
·
12 hours ago

Eli Lilly and Co Stock (LLY) Moved Up by 3.01% on Sep 14: Drivers Behind the Movement

TradingKey
·
14 hours ago

UnitedHealth Earnings Growth Outlook Unlikely to Change, UBS Says

MT Newswires Live
·
Yesterday

Dow Jones Top Company Headlines at 11 am ET: Microsoft Sets Limits for AI Models as Altman Details Control Risks | Dell's ...

Dow Jones
·
Yesterday

Roche, GSK's Lung-Cancer Drug Candidates Show Promise in China

Dow Jones
·
Yesterday

Eli Lilly Announces R$ 0.2 Per Unit Dividend for 3Q 2026 BDRs

Reuters
·
Yesterday

Evercore ISI Remains a Buy on UnitedHealth (UNH)

TIPRANKS
·
Yesterday

Perspective Therapeutics Enters Cancer Clinical Trial Collaboration With Merck; Shares Up Pre-Bell

MT Newswires Live
·
Yesterday

Perspective Therapeutics Partners with Merck to Test [212Pb]PSV359 with Keytruda in FAP-Α-Positive Solid Tumors

Reuters
·
Yesterday

Perspective Therapeutics, - Co Sponsors Study; Merck Provides Pembrolizumab at no Cost

THOMSON REUTERS
·
Yesterday

One State's Battle to Stop People from Taking Unapproved Weight-Loss Drugs

Dow Jones
·
Yesterday

Big Pharma is Pouring Billions into China's Biotechs

Dow Jones
·
Yesterday